课题基金 / 基金详情

项目摘要

项目成果

Marc Kevin Jenkins的其他基金

相似基金

相关文献

中文摘要
翻译
这个项目的长期目标是了解CD4+T细胞的机制 对存在于次级淋巴器官但不存在于胸腺的抗原的耐受性。此前,我们 显示在次级淋巴器官中暴露于模型抗原的幼稚CD4+T细胞 缺乏炎症的细胞增殖不良,然后大多数子代死亡,幸存者进入无能状态。 以淋巴因子产生不足为特征的状态。此应用程序的目标是确定 类似的一系列事件解释了外周对某些天然自身蛋白的耐受性。这已经成为一种 发现AIRE转录因子驱动胸腺外异位表达以来的紧迫问题 胸腺中的基因产物。因此,外周耐受性的生理作用仍然是可能的 被认为是真正发挥作用的是由艾尔介导的胸腺内耐受。在这里,我们将检验这一假设 外周耐受是与生理相关的,通过使用新的工具来识别耐受机制 这适用于两种妊娠特异性蛋白质,一种似乎受AIRE调控,另一种似乎受AIRE调控 不会,还有一种精子特异性蛋白质。我们将确定这些蛋白质是否具有免疫原性。 在从未在相关组织中表达过它们的小鼠(例如,未怀孕的雌性小鼠)中,并成为 在表达后的小鼠中无免疫原性(例如,怀孕的雌性小鼠)。相关抗原肽将 被鉴定并用于生产多肽-MHC II多聚体。然后,倍增器将与敏感的 一种新的检测每只小鼠少于100个细胞的富集法来计数多肽MHC II- 在多克隆内表达相关蛋白之前、期间和之后的特异性CD4+T细胞 正常小鼠的曲目。这种方法应该揭示相关的CD4+T细胞是否被删除, 转化为调节性细胞,或在这些发育调节期期间或之后变得无能 自我蛋白被表达出来。然后,这种方法将用于基因靶向的小鼠,以确定是否或 不是像Fas和Cbl-b这样的分子,以及P01其他成员确定的其他分子参与了 确定了耐受机制。成功将提供第一个明确的外围设备身份 适用于天然自身抗原的耐受机制。这些信息应该有助于将未来的研究集中在 了解相关机制,并阐明其失败并导致自身免疫的潜在途径。
英文摘要
The long-term goal of this project is an understanding of the mechanisms that account for CD4+ T cell tolerance to antigens that are presented in the secondary lymphoid organs but not the thymus. Previously, we showed that naive CD4+ T cells that are exposed to model antigens in the secondary lymphoid organs in the absence of inflammation proliferate poorly, then most of the progeny die, and the survivors enter an anergic state characterized by poor lymphokine production. The goal of this application is to establish whether or not a similar series of events accounts for peripheral tolerance to certain natural self-proteins. This has become a pressing issue since the discovery that the AIRE transcription factor drives ectopic expression of extrathymic gene products in the thymus. Thus, it remains possible that the physiological role that peripheral tolerance was thought to play is really played by AIRE-mediated intrathymic tolerance. Here, we will test the hypothesis that peripheral tolerance is physiologically-relevant by using new tools to identify the tolerance mechanisms that apply to two pregnancy-specific proteins, one that appears to be regulated by AIRE and another that does not, and one sperm-specific protein. We will determine whether or not these proteins are immunogenic in mice that have never expressed them in the relevant tissue (e.g., non-pregnant female mice), and become non-immunogenic in mice after expression (e.g., pregnant female mice). The relevant antigenic peptides will be identified and used to produce peptide-MHC II multimers. The multimers will then be used with a sensitive new enrichment method capable of detecting fewer than 100 cells per mouse to enumerate peptide MHC II- specific CD4+ T cells before, during, and after expression of the relevant protein within the polyclonal repertoires of normal mice. This approach should reveal whether or not the relevant CD4+ T cells are deleted, turn into regulatory cells, or become anergic during or after the period when these developmental^ regulated self-proteins are expressed. This approach will then be used in gene-targeted mice to determine whether or not molecules such as Fas and Cbl-b, and others identified by other members of the P01, are involved in the identified tolerance mechanism. Success would provide the first definitive identification of the peripheral tolerance mechanism that applies to a natural self-antigen. This information should help focus future research on the relevant mechanism and shed light on the potential ways that it could fail and lead to autoimmunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Detection and Activation of CD4+ T cells with Low Affinity TCRs
  • 批准号:
    10348758
  • 项目类别:
  • 资助金额:
    $38.32万
  • 财政年份:
    2019
  • 负责人:
    Marc Kevin Jenkins
  • 依托单位:
Detection and Activation of CD4+ T cells with Low Affinity TCRs
  • 批准号:
    10570243
  • 项目类别:
  • 资助金额:
    $38.32万
  • 财政年份:
    2019
  • 负责人:
    Marc Kevin Jenkins
  • 依托单位:
Protective CD4+ T Cells
  • 批准号:
    10349513
  • 项目类别:
  • 资助金额:
    $46.74万
  • 财政年份:
    2013
  • 负责人:
    Marc Kevin Jenkins
  • 依托单位:
Protective CD4+ T cells
  • 批准号:
    8430702
  • 项目类别:
  • 资助金额:
    $35.72万
  • 财政年份:
    2013
  • 负责人:
    Marc Kevin Jenkins
  • 依托单位:
海外基金